| Description |
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential[1].
|
| Related Catalog |
|
| In Vitro |
Adintrevimab 的 Fc 片段区域经过修饰以延长其半衰期。 Adintrevimab 与 SARS-CoV-2 刺突糖蛋白受体结合域中的一个独特表位结合，该表位与血管紧张素转换酶 2 结合位点部分重叠，在 sarbecoviruses 中高度保守。在体外，Adintrevimab 已证明对 SARS-CoV-2（包括 Alpha、Beta、Gamma 和 Delta）的大多数变体和亚系以及其他 SARS 样病毒具有有效的中和活性。Adintrevimab 对 Omicron BA.1/BA.1.1 的体外活性降低，对 BA.2、BA.3、BA.4 和 BA.5 缺乏活性[1]。
|
| In Vivo |
Adintrevimab（9.25、55、333 或 2,000μg；腹腔注射；一次）以剂量依赖性方式提供针对 SARS-CoV-2/WA1/2020 感染的保护[1]。 Adintrevimab（5-25mg/kg；静脉注射；一次）以剂量依赖性方式提供针对 SARS-CoV-2/WA1/2020 感染的保护[1]。 Animal Model: Syrian golden hamsters (5-6-week-old females; 75-125 g) infected with SARS-CoV-2/WA1/2020[1]. Dosage: 9.25, 55, 333, or 2,000 μg (average range: 0.1 to 20 mg/kg) Administration: Intraperitoneal injection; single dose Result: Showed significant reduction in lung viral load and virus-induced lung pathology. Animal Model: Rhesus macaques (5.6-8.8 years old; 6 females [4.4-6.3 kg] and 6 males [6.1-8.5 kg]) infected with SARS-CoV-2/WA1/2020[1]. Dosage: 5 mg/kg, 25 mg/kg Administration: Intravenous injection; single dose Result: Reduced pulmonary inflammation.
|
| References |
[1]. Elizabeth E Zumbrun, et al. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19. Antimicrob Agents Chemother. 2022 Dec 15;e0135322.
|
